The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B

Samer E. Kaba, Franco DeMonte, Janet M. Bruner, Athanassios P. Kyritsis, Kurt A. Jaeckle, Victor Levin, W. K.Alfred Yung

Research output: Contribution to journalArticlepeer-review

125 Scopus citations


OBJECTIVE: Recurrent malignant meningiomas and unresectable meningiomas represent a great therapeutic challenge after the failure of radiation therapy. No effective chemotherapy has been found. We report the preliminary results of the treatment of patients with recurrent unresectable or malignant meningiomas with recombinant interferon alpha-2B (IFN-α-2B). METHOD: Each of six patients with either a recurrent malignant meningioma or an unresectable meningioma was treated with IFN-α, administered subcutaneously at a dosage of 4 mU/m2 per day, 5 days per week. Two of the six meningiomas were regular, one was atypical, and three were malignant. RESULTS: Five of six patients exhibited positive response to treatment; with stabilization of the size of the tumor in four patients and slight regression in one. The responses observed lasted from 6 to 14 months. The toxicity associated with prolonged use of IFN-α was mild and well tolerated. CONCLUSION: These results suggest that IFN-α is effective in the treatment of recurrent malignant meningiomas.

Original languageEnglish (US)
Pages (from-to)271-275
Number of pages5
Issue number2
StatePublished - Feb 1997


  • Biological modifiers
  • Brain neoplasms
  • Interferon
  • Meningioma

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology


Dive into the research topics of 'The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B'. Together they form a unique fingerprint.

Cite this